2135 (2135) Fair Value & Analysis

Healthcare · Market cap HK$68.5M

2 2135 2135 · HK

PriceHK$0.1230

Fair ValueHK$0.1400

Upside+13.8%

Quality49/100

Watch 2135 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$0.1100 – HK$0.1400

Fair value as of: Jul 2, 2026

From 25 valuation models · updated today

Share price +0.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1070 – HK$0.1750 · fair‑value band HK$0.1100 – HK$0.1400 · the HK$0.1230 price screens below the HK$0.1400 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2135 (2135) currently trades at HK$0.1230, while our model-based Fair Value estimate is HK$0.1400 — implying the stock looks roughly 13.8% undervalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 2135 generated revenue of HK$189M at a net margin of 1.0%. Revenue grew 28.0% year over year. It earns a return on equity of -2.3%. Net debt stands at HK$1.4M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$189M

Revenue growth (YoY) +28.0%

Net margin 1.0%

Return on equity -2.3%

Free cash flow HK$32.0M FY2025

Operating margin 12.2%

More key figures

EPS (TTM) HK$-0.0100

EPS growth (YoY) +88.7%

Net debt HK$1.4M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2135 reported revenue of HK$185M in FY2025 versus HK$188M in FY2021, a compound −0.5%/yr. Reported net income was HK$1.8M in FY2025.

Revenue −0.5%/yr

FY21 HK$188M

FY22 HK$165M

FY23 HK$189M

FY24 HK$199M

FY25 HK$185M

Net income

FY21 −HK$17.7M

FY22 −HK$15.9M

FY23 −HK$32.5M

FY24 −HK$59.2M

FY25 HK$1.8M

Is 2135 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.47	$8.55	-25%
5225 5225	8.71 MYR	4.87 MYR	-44%
IHHHF IHHHF	$1.71	$1.17	-32%
Tenet Healthcare Corporation THC	$164.77	$280.85	+70%
Rede D'Or São Luiz S.A RDOR3	R$32.50	R$46.04	+42%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2135 (2135) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.1400 versus a price of HK$0.1230 — about +14% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2135?

Our model-based fair value for 2135 is HK$0.1400 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.1230.

What is the quality score of 2135?

2135 has a Quality Score of 49/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2135 (2135)?

2135 reported trailing-twelve-month revenue of about HK$189M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2135?

The net profit margin of 2135 is about 1.0%, meaning it keeps roughly 1.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.